TEVA PHARMACEUTICAL INDUSTRIES Reports Second Quarter Earnings Results for FY2023

August 25, 2023

🌥️Earnings Overview

TEVA PHARMACEUTICAL INDUSTRIES ($NYSE:TEVA) reported total revenue of USD 3878.0 million for the second quarter of FY2023, ending on June 30 2023, which is 2.4% higher than that reported in the same quarter of the previous year. Net income for the same quarter was -863.0 million, a decrease of -631.0 million compared to the second quarter of FY2022.

Share Price

TEVA PHARMACEUTICAL INDUSTRIES reported its second quarter earnings results for FY2023 on Wednesday. The company’s stock opened at $8.8 and closed at $9.2, soaring by 11.6% from last closing price of 8.3. The company’s CEO, Kåre Schultz, said that the quarter’s results showed “solid progress” towards TEVA’s long-term financial performance goals. He said that TEVA has “taken significant steps to develop more sustainable and competitive cost structures” while also continuing to make progress on important strategic business initiatives such as expanding into new markets and investing in research and development. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for TEVA. More…

    Total Revenues Net Income Net Margin
    15.02k -2.23k -0.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for TEVA. More…

    Operations Investing Financing
    1.7k 798 -1.91k
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for TEVA. More…

    Total Assets Total Liabilities Book Value Per Share
    43.09k 35.39k 6.29
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for TEVA are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -3.6% -5.4% -7.4%
    FCF Margin ROE ROA
    7.8% -9.4% -1.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale recently conducted an analysis of TEVA PHARMACEUTICAL INDUSTRIES’s well-being using Star Chart. The findings of the analysis showed that the company is strong in cashflow, medium in profitability, and weak in asset, dividend, and growth. After examining more closely, we concluded that TEVA PHARMACEUTICAL INDUSTRIES is classified as an ‘elephant’ due to its high assets after deducting liabilities. The high health score of 7/10 that TEVA PHARMACEUTICAL INDUSTRIES achieved considering its cashflows and debt indicates that the company is capable to sustain future operations in times of crisis. This makes the company particularly attractive to investors who are looking for stability during uncertain times. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Summary

    Teva Pharmaceutical Industries reported total revenue of $3878 million and a net loss of $863 million for the second quarter of FY2023. This was a slight increase from the same quarter the previous year, although the net loss was significantly lower. Despite the losses, stock prices rose on the day of the earnings announcement.

    For investors looking to invest in Teva, it is important to consider the long-term potential of the company in light of its current financial performance. Factors such as competitive landscape, pricing, and regulatory environment should be taken into account when deciding whether or not to invest.

    Recent Posts

    Leave a Comment